Pathfinder Cell Therapy (PFND) Inactive 10-Q2009 Q1 Quarterly report

Filed: 14 May 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: APB, applied, began, begun, case, cavity, classification, clearance, conserving, coupled, depreciation, ear, Eastern, embedded, ENT, exemption, feature, gynecologic, half, immaterial, indexed, instrument, Insufficient, Lattice, Middle, nasal, nose, orderly, pelvic, predict, priority, pronouncement, prospective, prospectively, purpose, quoted, recent, recoverability, reliance, reoperation, resolution, significant, significantly, SinusShield, statute, stent, sternotomy, stipulated, stockholder, throat, upgrade

Removed: advent, amendment, anterior, Approvable, artificial, avoid, cardiothoracic, collectibility, computer, contract, copolymer, corrective, delayed, depend, dilutive, efficacy, EU, expensed, factored, field, figure, filing, forced, formally, hiring, incorporated, injury, investing, launched, Letter, maintain, masked, matured, measuring, neonatal, nonfinancial, observed, obtaining, package, past, pertaining, pivotal, population, positive, Premarket, President, prevalent, primary, promissory, protocol, randomized, rate, reoccurrence, repayment, replacement, request, resin, review, revision, satisfactory, secondary, selected, soft, spinal, staged, stating, sterilization, supplementary, technique, underwent, vertebral, Vice, Warning, younger

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PFND similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXIBIT 32.1: CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

In connection with the accompanying Quarterly Report on Form 10-Q of SyntheMed, Inc. for the quarter ended March 31, 2009, the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

(1)

such Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in such Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 fairly presents, in all material respects, the financial condition and results of operations of SyntheMed, Inc.

Dated: May 13, 2009	By:	/s/ Robert P. Hickey
		Robert P. Hickey Chief Executive Officer and Chief Financial Officer

* A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided by SyntheMed, Inc. and will be retained by SyntheMed, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.